medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Discordance between gut-derived appetite hormones and energy intake in humans

Aaron Hengist[1], Christina M. Sciarrillo[1], Juen Guo[1], Mary Walter[1], Kevin D. Hall[1]*

[1]National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA

*Corresponding Author: kevin.hall@nih.gov

Abstract

Gut-derived hormones affect appetite. Ghrelin increases hunger and decreases after food intake, whereas satiation and satiety are induced by peptide YY (PYY), glucagon-like peptide-1 (GLP-1), and perhaps glucose-dependent insulinotropic polypeptide (GIP) which are increased after food intake [1-3]. These gut-derived appetite hormones have been theorized to play a role in the weight-loss that results from bariatric surgery [4, 5] and agonists of GLP-1 and GIP receptors have become successful medical treatments for obesity [6-8]. Circulating concentrations of gut-derived appetite hormones can be influenced by dietary macronutrient composition [9-13], which provides a theoretical basis for why some diets may help facilitate weight loss better than others. We investigated inpatient adults in a randomized crossover study and demonstrated that, after 2 weeks of eating a low carbohydrate (LC) diet (75.8% fat, 10.0% carbohydrate), a LC meal resulted in significantly greater postprandial GLP-1, GIP, and PYY but lower ghrelin compared to an isocaloric low fat (LF) meal after 2 weeks of eating a LF diet (10.3% fat, 75.2% carbohydrate; all $p \leq 0.02$). However, the observed differences in gut-derived appetite hormones were incommensurate with subsequent ad libitum energy intake across the day, which was 551±103 kcal ($p<0.0001$) greater following the LC diet as compared to the LF diet. These data suggest that other diet-related factors can dominate the effects of gut-derived appetite hormones on ad libitum energy intake, at least in the short-term.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

We recently studied 20 inpatient adults who were exposed to two diets varying widely in the proportion of fat to carbohydrate for periods of 2 weeks each in random order [14]. At the end of each ad libitum feeding period, the LC diet resulted in greater fasting concentrations of GLP-1 and GIP, but similar concentrations of PYY and leptin, and lower concentrations of total ghrelin and active ghrelin, when compared to the LF diet (**Table 1**). **Fig. 1** demonstrates that the LC breakfast test meal delivered at the end of the ad libitum LC period resulted in greater mean postprandial plasma concentrations of active GLP-1 (LC meal: 6.44±0.78 pg·mL^{-1}, LF meal: 2.46±0.26 pg·mL^{-1}; p<0.0001), GIP (LC meal: 578±60 pg·mL^{-1}, LF meal: 319±37 pg·mL^{-1}; p=0.0002), and PYY (LC meal: 65.6±5.6 pg·mL^{-1}, LF meal: 50.7±3.8 pg·mL^{-1}; p=0.02) whereas total ghrelin (LC meal: 184±25 pg·mL^{-1}, LF meal: 261±47 pg·mL^{-1}; p=0.0009), active ghrelin (LC meal: 91±9 pg·mL^{-1}, LF meal: 232±28 pg·mL^{-1}; p<0.0001), and leptin (LC meal: 26.9±6.5 ng·mL^{-1}, LF meal: 35.2±7.5 ng·mL^{-1}; p=0.01) were lower as compared to an isocaloric LF breakfast test meal delivered at the end of the ad libitum LF period.

After the breakfast test meal, ad libitum energy intake was greater during the LC diet at lunch (244±85 kcal; p=0.008) and dinner (193±86 kcal; p=0.04), but not snacks (114±63 kcal; p=0.12), such that the total ad libitum energy intake over the rest of the day was significantly greater (551±103 kcal; p<0.0001) as compared to when the same participants consumed the LF diet (**Fig. 2**). Within each diet pattern, there were no significant correlations between subsequent ad libitum energy intake and the mean postprandial active GLP-1 (LC diet: r=-0.1; p=0.68, LF diet: r=-0.12; p=0.60), GIP (LC diet: r=-0.08; p=0.73, LF diet: r=0.23; p=0.34), PYY (LC diet: r=-0.23; p=0.32, LF diet: r=-0.007; p=0.98), total ghrelin (LC diet: r=0.31; p=0.19, LF diet: r=0.32; p=0.16), active ghrelin (LC diet: r=0.20; p=0.41, LF diet: r=0.07; p=0.76), or leptin (LC diet: r=-0.07; p=0.77, LF diet: r=-0.26; p=0.27). The observed differences in gut-derived appetite hormones during the LC test meal would be expected to result in reduced appetite and lower ad libitum energy intake as compared to the LF diet. However, the opposite result was observed, with the LC diet resulting in an additional ~500 kcal consumed over the remainder of the day following the test meal, as compared to the LF diet. This difference was similar to the overall ~700 kcal·d^{-1} difference between the diets averaged over two weeks [14].

Only decreased concentrations of the adipokine leptin were commensurate with the direction of ad libitum energy intake differences between the LC and LF diets. The decrease in leptin following

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

the LC diet is in agreement with previous evidence comparing a ketogenic low carbohydrate diet with an isocaloric diet moderate in both carbohydrate and fat [15]. The decrease in leptin following LC is likely explained by decreased insulin and glucose concentrations, which were lower in LC compared to LF [14]. Previous studies have shown that small increases in insulin induced by glucose infusion of 2.5 $mg \cdot kg^{-1} \cdot min$ were sufficient to offset the decrease in leptin observed with 16 hours of fasting [16] and 24 hours of ketogenic carbohydrate restriction reduced leptin concentrations independent from changes in ad libitum energy intake and preceding changes in adiposity [17]. Therefore, the evidence suggests that changes in carbohydrate availability, rather than energy intake or energy balance, are key for altering leptin concentrations. Decreased leptin would theoretically increase appetite, as has been associated following weight loss [18]. Whilst it is possible that leptin, as a longer-term appetite signal, overrides the transient signals from gut-derived hormones, leptin concentrations did not correlate with ad libitum energy intake in the present study, so it is likely that other diet-related factors are more important in this context.

The diet differences in gut hormone responses may be explained by macronutrient composition of the diets and/or meals. The propensity for specific nutrients or foods to alter endogenous gut hormone concentrations has been reviewed previously [19, 20]. Early evidence suggested that small increases in GLP-1 were observed after isocaloric carbohydrate (glucose), fat (double cream), or protein (lean turkey) ingestion, whereas GIP only responded to carbohydrate and fat [21]. However, irrespective of nutrient, the food matrix also plays a large role in determining postprandial responses as demonstrated by isocaloric ingestion of glucose eliciting greater GLP-1 and GIP responses than brown rice or pearl barley [21]. With regards to carbohydrate manipulation, the increase in PYY observed following LC in the present study resembles the results of a similar randomized crossover study in participants with obesity who consumed isocaloric low-carbohydrate or low-fat diets for one week before ingesting a representative breakfast meal [22]. Similarly, high-fat drinks (38% carbohydrate, 50% fat) increase postprandial GLP-1 and PYY responses, without differences in postprandial ghrelin responses, compared to isocaloric (590 kcal) low-fat, high-carbohydrate drinks (84% carbohydrate, 3% fat), but these differences did not translate into differences in ad libitum energy intake in a subsequent lunch meal [10]. Instead, ad libitum intake was associated with ghrelin responses, which contrasts with our results because total and active ghrelin were reduced with the LC diet in comparison to the LF diet and did not correlate with energy intake.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Macronutrient manipulation, with food volume and energy density controlled, has been shown to alter postprandial GLP-1, GIP, PYY, active ghrelin, and total ghrelin responses, but did not alter subjective hunger or subsequent energy intake [9, 12, 13]. Over the course of our study, the LF diet resulted in ~700 kcal·d^{-1} less ad libitum energy intake as compared to the LC diet without significant differences in self-reported appetite [14]. Because postprandial responses of gut-derived appetite hormones depend on the amount of food consumed [23, 24], the expected diet differences in postprandial ghrelin, GLP-1, GIP, and PYY during the ad libitum period would likely be even greater than we observed following the isocaloric meal tests and further emphasizes that the expected effects of these appetite hormone differences were dominated by other diet differences.

Recent analysis of meals from our inpatient feeding studies suggests that energy density, eating rate, and proportion of hyper-palatable foods are positively associated with energy intake [25]. Greater dietary energy density has consistently been shown to increase energy intake [26] and the LC diet had about double the energy density of the LF diet, a difference that mediated 24.4±5.5% of the diet effect on meal energy intake [25]. A quicker eating rate increases energy intake of presented meals without altering subsequent hunger [27]. This could be related to sensory and physical properties of foods, like food texture [28]; for example, softer, less solid, less viscous foods are associated with increased eating rate [29]. Interestingly, eating rate of the LF diet was quicker than the LC diet in our study when expressed in grams per minute, but the higher energy density of the LC diet resulted in a greater eating rate than the LF diet when expressed in energy consumed per minute [14]. Hyper-palatable foods have recently been defined by quantitative thresholds of nutrient combinations (fat and sugar, fat and sodium, or carbohydrates and sodium) that may drive excess intake [30]. In our study, the LC diet had a greater proportion of hyper-palatable foods than the LF diet and mediated 13.9±4.0% of the diet effect on meal energy intake [25]. The availability of hyperpalatable foods in the US food system has increased from around 49% to around 69% in 30 years [31]. Emerging evidence suggests that hyper-palatable foods may be more rewarding [32], and that consumption is disproportionately increased during binge eating episodes in patients with bulimia nervosa [33]. Whilst these factors may often be inter-related in real world settings, it is important for future work to isolate these diet-related factors and test their contribution to ad libitum energy intake in different dietary contexts.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Discordance between gut hormone responses and energy intake in the present study may appear to contradict the recent success of GLP-1 receptor agonists, but quantitative considerations of dose and exposure reconcile our findings. Specifically, the estimated active GLP-1 steady state average exposure concentration, C_{avg}, for the present study had mean (95% CI) values of 0.034 (0.029, 0.043) nmol·L^{-1} for LF and 0.086 (0.071, 0.113) nmol·L^{-1} for LC, which are orders of magnitude lower than the C_{avg} of both oral and subcutaneous semaglutide ranging from ~3 nmol·L^{-1} up to ~30 nmol·L^{-1} with oral and subcutaneous semaglutide, respectively [34]. Such high C_{avg} with pharmacological treatment is due to the long half-life of semaglutide which has a similar binding affinity to the GLP-1 receptor as native GLP-1 [35]. Furthermore, pharmacological engagement of the GLP-1 receptor may act differently from nutrient-stimulated gut hormones. For example, endogenous GLP-1 may affect the hypothalamus through neuronal signaling from the gut to brain via solitary tract neurons, whereas exogenous GLP-1 receptor agonists may directly engage hypothalamic and brainstem GLP-1 receptors [8]. With this context, changes in endogenous gut hormone concentrations induced by diet may be too weak to affect energy intake. Indeed, mouse models that knockout the GLP-1 receptor [36] or delete intestinal GLP-1 production [37] do not result in a body weight or food intake phenotype, suggesting that endogenous GLP-1 has a limited effect on appetite in the normal physiological range.

Some forms of bariatric surgery result in substantial increases in postprandial GLP-1 and PYY [38-40], likely due to altered gastric emptying and intestinal nutrient delivery. It is thought that the magnitude of the post-surgical changes in postprandial gut hormone responses are mechanistically linked to reduced appetite and energy intake. Infusion of GLP-1, PYY, and oxyntomodulin in healthy participants that mimics the concentrations observed following Roux-en-Y gastric bypass reduced energy intake at lunch and dinner by ~400 kcal (32%) [2]. The active GLP-1 and PYY concentrations achieved were around 26 pmol·L^{-1} (85 pg·mL^{-1}) and 80 pmol·L^{-1} (320 pg·mL^{-1}) respectively. For active GLP-1, these concentrations are around 13-fold and 35-fold greater than mean postprandial concentrations following the LC and LF meals in the present study, and for PYY they are around 5-fold and 6-fold greater. This again suggests that substantially greater increases in gut hormone concentrations are required to have meaningful effects on appetite and energy intake, likely greater than is achievable by diet interventions alone.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

A limitation of the current study is that participants had no choice regarding the foods available for consumption. They could only choose the quantity of the foods eaten. While the gut-derived appetite hormones were not a dominant factor determining energy intake in this setting, it is possible that such differences in appetite hormones in a real-world setting might alter food choices at subsequent meals and thereby alter energy intake. Nevertheless, our study suggests that differences in dietary factors like energy density or proportion of hyper-palatable foods may play a greater role in appetite regulation than endogenous gut-derived appetite hormones, at least in the short term. Future research should aim to identify such diet differences that influence energy intake and evaluate whether their effects and their potential discordance with gut-dervied appetite hormones persist over time.

Methods

These data are exploratory endpoints from a registered clinical trial conducted at the Metabolic Clinical Research Unit at the NIH Clinical Center and approved by the institutional board of the National Institute of Diabetes & Digestive & Kidney Diseases (NCT03878108). Detailed methods have been published previously [14]. In brief, at the end of the second inpatient week of consuming either an ad libitum low carbohydrate (LC) or low fat (LF) diets and after an overnight fast, 20 adults (male n=11, female n=9; mean±SD, age 30±6 years; body mass 80.8±18.2 kg; body mass index 27.8±5.9 $kg \cdot m^{-2}$; fat mass 26.9±11.2 kg; body fat percentage 32.8±9.8%; resting energy expenditure 1550±287 $kcal \cdot d^{-1}$) consumed liquid meals matching the macronutrient content of the prevailing diet and amounting to 30% of the estimated daily calorie requirements as determined by 1.6 multiplied by the resting energy expenditure measured at screening. Mean (range) of energy in the test meals was 777 (532 to 1043) kcal. The LC test meal was 10% carbohydrate, 75% fat, and 15% protein whereas the LF test meal was 75% carbohydrate, 10% fat, and 15% protein. Blood samples were obtained at 0, 10, 20, 30, 60, 90, 120, 180, 240, 300, and 360 minutes after the meals in tubes containing a protease inhibitor cocktail (including DPPIV inhibitor and aprotinin) to measure GLP-1, GIP, PYY, total ghrelin, active ghrelin, and leptin using multiplex immunoassays (Meso Scale Diagnostics).

After the breakfast mixed meal tests, ad libitum food intake was measured over the rest of the day including lunch, dinner, and snacks by weighing the remaining food and beverages to

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

calculate the amount of each food consumed and energy intake was calculated using ProNutra software (v.3.4, Viocare) with nutrient values derived from the USDA National Nutrient Database for Standard Reference, Release 26 and the USDA Food and Nutrient Database for Dietary Studies, 4.0. Statistical analyses were performed using SAS (v.9.4; SAS Institute) and Prism (v.9.5.0; GraphPad). Mean plasma concentrations were calculated by dividing total area under the curve (tAUC) by 360 minutes. Active GLP-1 C_{avg} was estimated by multiplying the 6-hour postprandial tAUC by 3 (18 h) and multiplying the postabsorptive (fasting) concentration by 360 minutes (6 h), to get 24-hour exposure, and dividing by 24. The conversion factor used for GLP-1 was 1 $pmol \cdot L^{-1}$ = 3.287 $pg \cdot mL^{-1}$. Data were checked for normality using Shapiro-Wilk test, differences between conditions were assessed using paired t-tests for normally distributed and Wilcoxon tests for non-normally distributed data. Simple linear correlation was used to explore associations between gut hormone responses and ad libitum energy intake. Significance was accepted as $p \leq 0.05$.

Acknowledgements

This work was supported by the Intramural Research Program of the NIH, National Institute of Diabetes & Digestive & Kidney Diseases under award number 1ZIADK013037. We thank the nursing and nutrition staff at the NIH Metabolic Clinical Research Unit for their invaluable assistance with this study. We thank the study participants for their invaluable contribution.

Author contributions

KDH designed the study, MW performed the biochemical analyses, JG and KDH analyzed the data, AH, CMS, JG, and KDH interpreted the data, drafted the manuscript, and approved the final version.

Competing interests

The authors declare no competing interests.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Tables

Table 1. Fasting concentrations of gut-derived appetite hormones and leptin in the second week of low carbohydrate (LC) or low fat (LF) diet. Data are mean ± SEM, n=20.

	LC	LF	*p* value LC *vs* LF
Active GLP-1 ($pg \cdot mL^{-1}$)	0.96 ± 0.14	0.61 ± 0.06	0.01
GIP ($pg \cdot mL^{-1}$)	80 ± 13	56 ± 8	0.03
PYY ($pg \cdot mL^{-1}$)	38.2 ± 3.2	38.0 ± 3.7	0.94
Total ghrelin ($pg \cdot mL^{-1}$)	263 ± 48	329 ± 55	0.004
Active ghrelin ($pg \cdot mL^{-1}$)	116 ± 21	238 ± 30	0.0002
Leptin ($ng \cdot mL^{-1}$)	28.2 ± 6.7	33.5 ± 7.8	0.39

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figures

Figure 1. Postprandial a) active glucagon-like peptide-1 (GLP-1), b) glucose-dependent insulinotropic polypeptide (GIP), c) peptide YY (PYY), d) leptin, e) total ghrelin, and f) active ghrelin responses to isocaloric low carbohydrate (LC) or low fat (LF) meals following habituation to each diet in a randomized crossover design. Mean (range) of energy in the test meals was 777 (532 to 1043) kcal. Data are mean ± SEM. n=20.



medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 2. Total energy intake (EI), and energy intake from lunch, dinner, and snacks throughout the day after isocaloric low carbohydrate (LC) or low fat (LF) meals following habituation to each diet in a randomized crossover design. Mean (range) of energy in the test meals was 777 (532 to 1043) kcal. Data are mean ± SEM and individual responses. n=20.



medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

References

1. Sato T, Nakamura Y, Shiimura Y, Ohgusu H, Kangawa K, Kojima M: **Structure, regulation and function of ghrelin**. *J Biochem* 2012, **151**(2):119-128.
2. Tan T, Behary P, Tharakan G, Minnion J, Al-Najim W, Albrechtsen NJW, Holst JJ, Bloom SR: **The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers**. *The Journal of clinical endocrinology and metabolism* 2017, **102**(7):2364-2372.
3. Samms RJ, Goghlan MP, Sloop KW: **How May GIP Enhance the Therapeutic Efficacy of GLP-1?** *Trends in Endocrinology and Metabolism* 2020, **31**(6):410-421.
4. Holst JJ, Madsbad S, Bojsen-Moller KN, Svane MS, Jorgensen NB, Dirksen C, Martinussen C: **Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss**. *Surg Obes Relat Dis* 2018, **14**(5):708-714.
5. Troke RC, Tan TM, Bloom SR: **The future role of gut hormones in the treatment of obesity**. *Ther Adv Chronic Dis* 2014, **5**(1):4-14.
6. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC *et al*: **Tirzepatide Once Weekly for the Treatment of Obesity**. *N Engl J Med* 2022, **387**(3):205-216.
7. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA *et al*: **Once-Weekly Semaglutide in Adults with Overweight or Obesity**. *N Engl J Med* 2021, **384**(11):989-1002.
8. Drucker DJ, Holst JJ: **The expanding incretin universe: from basic biology to clinical translation**. *Diabetologia* 2023.
9. Foster-Schubert KE, Overduin J, Prudom CE, Liu J, Callahan HS, Gaylinn BD, Thorner MO, Cummings DE: **Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates**. *The Journal of clinical endocrinology and metabolism* 2008, **93**(5):1971-1979.
10. Gibbons C, Caudwell P, Finlayson G, Webb DL, Hellstrom PM, Naslund E, Blundell JE: **Comparison of postprandial profiles of ghrelin, active GLP-1, and total PYY to meals varying in fat and carbohydrate and their association with hunger and the phases of satiety**. *The Journal of clinical endocrinology and metabolism* 2013, **98**(5):E847-855.
11. Helou N, Obeid O, Azar ST, Hwalla N: **Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females**. *Ann Nutr Metab* 2008, **52**(3):188-195.
12. van der Klaauw AA, Keogh JM, Henning E, Trowse VM, Dhillo WS, Ghatei MA, Farooqi IS: **High Protein Intake Stimulates Postprandial GLP1 and PYY Release**. *Obesity* 2013, **21**(8):1602-1607.
13. Raben A, Agerholm-Larsen L, Flint A, Holst JJ, Astrup A: **Meals with similar energy densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intake**. *Am J Clin Nutr* 2003, **77**(1):91-100.
14. Hall KD, Guo J, Courville AB, Boring J, Brychta R, Chen KY, Darcey V, Forde CG, Gharib AM, Gallagher I *et al*: **Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake**. *Nat Med* 2021, **27**(2):344-353.
15. Hall KD, Chen KY, Guo J, Lam YY, Leibel RL, Mayer LE, Reitman ML, Rosenbaum M, Smith SR, Walsh BT *et al*: **Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men**. *Am J Clin Nutr* 2016, **104**(2):324-333.
16. Sonnenberg GE, Krakower GR, Hoffmann RG, Maas DL, Hennes MM, Kissebah AH: **Plasma leptin concentrations during extended fasting and graded glucose infusions: relationships with changes in glucose, insulin, and FFA**. *The Journal of clinical endocrinology and metabolism* 2001, **86**(10):4895-4900.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

17. Hengist A, Davies RG, Rogers PJ, Brunstrom JM, van Loon LJC, Walhin JP, Thompson D, Koumanov F, Betts JA, Gonzalez JT: **Restricting sugar or carbohydrate intake does not impact physical activity level or energy intake over 24 h despite changes in substrate use: a randomised crossover study in healthy men and women**. *Eur J Nutr* 2022.
18. Keim NL, Stern JS, Havel PJ: **Relation between circulating leptin concentrations and appetite during a prolonged, moderate energy deficit in women**. *Am J Clin Nutr* 1998, **68**(4):794-801.
19. Bodnaruc AM, Prud'homme D, Blanchet R, Giroux I: **Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review**. *Nutr Metab (Lond)* 2016, **13**:92.
20. Watkins JD, Koumanov F, Gonzalez JT: **Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review**. *Adv Nutr* 2021, **12**(6):2540-2552.
21. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V: **Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns**. *J Endocrinol* 1993, **138**(1):159-166.
22. Essah PA, Levy JR, Sistrun SN, Kelly SM, Nestler JE: **Effect of macronutrient composition on postprandial peptide YY levels**. *Journal of Clinical Endocrinology & Metabolism* 2007, **92**(10):4052-4055.
23. Hengist A, Edinburgh RM, Davies RG, Walhin JP, Buniam J, James LJ, Rogers PJ, Gonzalez JT, Betts JA: **Physiological responses to maximal eating in men**. *The British journal of nutrition* 2020, **124**(4):407-417.
24. Lewis HB, Ahern AL, Solis-Trapala I, Walker CG, Reimann F, Gribble FM, Jebb SA: **Effect of reducing portion size at a compulsory meal on later energy intake, gut hormones, and appetite in overweight adults**. *Obesity (Silver Spring)* 2015, **23**(7):1362-1370.
25. Fazzino TL, Courville AB, Guo J, Hall KD: **Ad libitum meal energy intake is positively influenced by energy density, eating rate and hyper-palatable food across four dietary patterns**. *Nat Food* 2023.
26. Robinson E, Khuttan M, McFarland-Lesser I, Patel Z, Jones A: **Calorie reformulation: a systematic review and meta-analysis examining the effect of manipulating food energy density on daily energy intake**. *Int J Behav Nutr Phy* 2022, **19**(1).
27. Robinson E, Almiron-Roig E, Rutters F, de Graaf C, Forde CG, Smith CT, Nolan SJ, Jebb SA: **A systematic review and meta-analysis examining the effect of eating rate on energy intake and hunger**. *Am J Clin Nutr* 2014, **100**(1):123-151.
28. Forde CG, de Graaf K: **Influence of Sensory Properties in Moderating Eating Behaviors and Food Intake**. *Frontiers in Nutrition* 2022, **9**.
29. Appleton KM, Newbury A, Almiron-Roig E, Yeomans MR, Brunstrom JM, de Graaf K, Geurts L, Kildegaard H, Vinoy S: **Sensory and physical characteristics of foods that impact food intake without affecting acceptability: Systematic review and meta-analyses**. *Obesity Reviews* 2021, **22**(8).
30. Fazzino TL, Rohde K, Sullivan DK: **Hyper-Palatable Foods: Development of a Quantitative Definition and Application to the US Food System Database**. *Obesity* 2019, **27**(11):1761-1768.
31. Fazzino TL, Bjorlie K, Rohde K, Smith A, Yi R: **Choices Between Money and Hyper-Palatable Food: Choice Impulsivity and Eating Behavior**. *Health Psychol* 2022, **41**(8):538-548.
32. Demeke S, Rohde K, Chollet-Hinton L, Sutton C, Kong KL, Fazzino TL: **Change in hyper-palatable food availability in the US food system over 30 years: 1988-2018**. *Public health nutrition* 2023, **26**(1):182-189.
33. Bjorlie K, Forbush KT, Chapa DAN, Richson BN, Johnson SN, Fazzino TL: **Hyper-palatable food consumption during binge-eating episodes: A comparison of intake during binge eating and restricting**. *Int J Eat Disorder* 2022, **55**(5):688-696.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.10.23289718; this version posted May 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

34. Overgaard RV, Hertz CL, Ingwersen SH, Navarria A, Drucker DJ: **Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes**. *Cell Rep Med* 2021, **2**(9):100387.
35. Overgaard RV, Navarria A, Ingwersen SH, Baekdal TA, Kildemoes RJ: **Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials**. *Clin Pharmacokinet* 2021, **60**(10):1335-1348.
36. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: **Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene**. *Nat Med* 1996, **2**(11):1254-1258.
37. Song Y, Koehler JA, Baggio LL, Powers AC, Sandoval DA, Drucker DJ: **Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice**. *Cell Metab* 2019, **30**(5):976-986 e973.
38. Lampropoulos C, Alexandrides T, Tsochatzis S, Kehagias D, Kehagias I: **Are the Changes in Gastrointestinal Hormone Secretion Necessary for the Success of Bariatric Surgery? A Critical Review of the Literature**. *Obes Surg* 2021, **31**(10):4575-4584.
39. Papamargaritis D, le Roux CW: **Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?** *Nutrients* 2021, **13**(3).
40. Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, Adamo M, Finer N, Fiennes AG *et al*: **Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans**. *Obes Surg* 2014, **24**(2):241-252.